Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
about
Androgens for the anaemia of chronic kidney disease in adultsErythropoietin or darbepoetin for patients with cancerDrug therapy for the management of cancer-related fatigueErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataDrug therapy for the management of cancer related fatigueErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataAndrogens for the anaemia of chronic kidney disease in adultsAnemia of chronic disease: a harmful disorder or an adaptive, beneficial response?AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival.Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished dataRecombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE.Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trialErythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors.Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancerComparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.Assessing the quality of prescribing and monitoring erythropoiesis-stimulating agents in the nursing home setting.Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.Patterns of erythropoiesis-stimulating agent use for chemotherapy-induced anemia in lung cancer: results of a retrospective Hungarian real-life clinical data analysis.Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies.Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression.Medicare coverage for erythropoiesis-stimulating agents: the perfect stormErythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance.The ESA APPRISE Oncology Program: A History of REMS Requirements, a Review of the Data, And an Approach to Compliance in the Hospital.Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial.AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agentsThe Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI.Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carcinoma xenografts exposed to surgical trauma.Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines.Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Cancer-related fatigue: clinical practice versus practice guidelines.Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies - results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers.An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost.Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.
P2860
Q24193138-0107333E-B4E8-4672-ABF5-587F0980F06FQ24202335-16041FD4-92CB-4173-882B-36779A5F2ED5Q24234267-8966763D-4B98-4C53-9467-9FFB297082DFQ24240202-A8481107-74BC-404F-867B-B7544539B8CAQ24242050-BB900EBB-13D1-46A2-A53C-B5BCB50B9824Q24242864-6DE04D4F-94A7-4A55-823C-253762B6D228Q24242990-167B3F0D-97BE-4037-8738-2B4D9DEDEF11Q24651385-23C74B51-3F89-43F0-84C5-C0AD16288A88Q27343148-FCF0CEF6-158D-483A-B2E5-4EBA2C4BAE6CQ30453014-599C28A2-2734-4C33-8E8F-60F1CA41B431Q30803363-DA20A674-1651-4DD4-ABDB-69D203692D86Q33243661-74913870-E241-4460-8025-92BB807EA7C5Q33288270-6459F2B0-DEDD-4487-8B8A-FD50E0FBE7AAQ33326648-4740D2E5-2165-4C0A-B5E8-08675F880A79Q33499897-01CC05A2-8ABF-4227-8CCB-04F4B20A364EQ33630871-8EFDE163-257E-40AA-8395-365E799E8F7AQ33654147-EA21D438-1A9A-42E9-87EA-15316E44F347Q33659628-BF57962F-426D-4C94-AF0B-80CD2B76DBE5Q33727356-EF2D6992-4860-446D-9DDF-3C7779579131Q33757650-746701EA-0789-489E-9FB0-87A2CA2E3EBEQ33827405-D1694DAC-9F30-451C-987A-31627E63E637Q33867969-2B82AE91-5996-4D76-A4F5-B9DAB2BB49E4Q33890476-2EE9F554-00A2-4DE3-B995-63B06DE9804CQ33920934-0B0F1216-451F-4511-8608-F92D3C605908Q33932540-ADD49134-4E49-4244-9049-CF03BB11B987Q34006181-FCDCB714-AC7F-4902-8FCA-ABCB4E840441Q34022950-EC9D3562-3DFF-462D-BA55-62BE19B72279Q34024987-E7F27D0B-7FDE-4D87-B3D0-73C8AAA395A9Q34042768-B8982CA3-5BB7-4D70-BEA8-E5810A0BD97DQ34068226-57B87EDE-CFA3-4140-A6D5-132A82AE282AQ34095827-8FBEC5DC-272D-4A9B-8C6F-B0F8A1196045Q34193545-B9CC66D0-FF5A-4625-A678-83E69CF3A324Q34217187-C460A69C-504E-435E-AF07-F1DC004E28D4Q34399172-1B337CFE-13EC-4E83-9FF9-C1BAAAB3CA16Q34624263-FCE83B1A-1996-43F1-9AF6-8FF90D5A4AC2Q34635638-9A7553AF-3B71-416B-9F22-49D244971534Q34700299-010BB0BF-5CAF-486F-8D6E-A38BF21F0049Q34810071-95F26212-AC43-4B85-86FA-4EA4AA6ED0B0Q34896347-E2E9D47A-BC06-450F-9175-CB8D92CD8A36Q34961213-48FA51A3-5A61-41EE-90E4-6C1AA0BCCDE3
P2860
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Maintaining normal hemoglobin ...... hemotherapy: a survival study.
@ast
Maintaining normal hemoglobin ...... hemotherapy: a survival study.
@en
type
label
Maintaining normal hemoglobin ...... hemotherapy: a survival study.
@ast
Maintaining normal hemoglobin ...... hemotherapy: a survival study.
@en
prefLabel
Maintaining normal hemoglobin ...... hemotherapy: a survival study.
@ast
Maintaining normal hemoglobin ...... hemotherapy: a survival study.
@en
P2093
P356
P1476
Maintaining normal hemoglobin ...... hemotherapy: a survival study.
@en
P2093
Antoly Makhson
Anton Roth
Brian Leyland-Jones
David Dodwell
Edouard Voznyi
Els Vercammen
George Manikhas
Konstantinas Valuckas
Marek Pawlicki
Mikhail Biakhov
P304
P356
10.1200/JCO.2005.06.150
P407
P577
2005-08-08T00:00:00Z